Umoja wa Ulaya - Kilithuania - EMA (European Medicines Agency)

recordati rare diseases - tocofersolan - cholestasis; vitamin e deficiency - vitaminai - vedrop skirtas vitamino e trūkumui, dėl virškinimo malabsorbcijos vaikams, kurie kenčia nuo įgimtas lėtiniu tulžies stazė ar paveldimas lėtiniu tulžies stazė, nuo gimimo (terminas naujagimiams) iki 16 ar 18 metų amžiaus, priklausomai nuo regiono.

Umoja wa Ulaya - Kilithuania - EMA (European Medicines Agency)

regeneron uk limited - rilonacept - cryopyrin susijusių periodiškai sindromai - imunosupresantai - rilonaceptas regeneron skirtas su kriopirinu susiję periodiniai sindromai (sksps) gydymui su sunkiu ligos simptomai, įskaitant šeiminės šalčio autoimunine sindromo (ŠŠas) ir muckle wells sindromas (mws), suaugusiesiems ir vaikams nuo 12 metų ir vyresnio amžiaus.

Umoja wa Ulaya - Kilithuania - EMA (European Medicines Agency)

accord healthcare s.l.u. - lakozamidas - epilepsija - antiepileptics, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Umoja wa Ulaya - Kilithuania - EMA (European Medicines Agency)

accord healthcare s.l.u. - buprenorphine hydrochloride, naloxone hydrochloride dihydrate - opioidų sutrikimai - kiti nervų sistemos vaistai - substitucinis opioidų priklausomybės gydymas, atsižvelgiant į medicininį, socialinį ir psichologinį gydymą. naloksono komponento tikslas yra atgrasyti nuo netinkamo vartojimo į veną. gydymas skirtas vartoti suaugusiesiems ir paaugliams, vyresniems nei 15 metų, kurie sutiko gydytis nuo priklausomybės.

Umoja wa Ulaya - Kilithuania - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - lanadelumab - angioedema, paveldima - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.

Umoja wa Ulaya - Kilithuania - EMA (European Medicines Agency)

ucb pharma s.a. - lakozamidas - epilepsijos, dalinis - antiepileptics, - lacosamide ucb yra nurodyta kaip monotherapy ir adjunctive terapijos gydymo dalies pasireiškė traukuliai su ar be antrinės apibendrinimo suaugusiems, paaugliams ir vaikams nuo 4 metų amžiaus, su epilepsija.

Umoja wa Ulaya - Kilithuania - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artritas, reumatas - imunosupresantai - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Umoja wa Ulaya - Kilithuania - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - kiti nervų sistemos vaistai - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Umoja wa Ulaya - Kilithuania - EMA (European Medicines Agency)

extrovis eu ltd. - lakozamidas - epilepsija - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Umoja wa Ulaya - Kilithuania - EMA (European Medicines Agency)

eli lilly nederland b.v. - insulinas glarginas - cukrinis diabetas - narkotikai, vartojami diabetu - cukrinio diabeto gydymas suaugusiems, paaugliams ir vaikams nuo 2 metų.